Navigation Links
BioMagnetics Diagnostics Corp. Rated 'Speculative Buy,' Target Price $1.42 by Beacon Equity Research
Date:3/13/2008

DALLAS, March 13 /PRNewswire/ -- BioMagnetics Diagnostics Corp. (Pink Sheets: BMGP) has been rated Speculative Buy with a price target of $1.42 by Beacon Equity Research Analyst, Lisa Springer, CFA.

The full report is available at http://www.BeaconEquity.com.

Anyone interested in receiving alerts regarding BioMagnetics Diagnostics research should email members@beaconequity.com with "BMGP" in the subject line.

In the report, the analyst writes, "Biomagnetics Diagnostics Corp. (BMGP) is a biotechnology company engaged in the discovery, development and marketing of new and innovative diagnostic equipment and immunoassays. The Company, through its wholly owned subsidiary, Bio-Spectrum Technologies, Inc., develops and patents potentially revolutionary diagnostic technologies.

"BMGP's flagship product, the High Throughput Screening-Magnetic Testing Platform (HTS-MTP) diagnostic system, is designed to detect any pathogen -- viral or bacterial -- using any body fluid as the testing median. It is the only system that measures viral load concomitantly with detection. Moreover, using the HTS-MTP system, multiple tests can be performed in one assay in a matter of minutes; that is several hundred percent more assays per hour than existing technologies at a fraction of the cost."

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of BioMagnetics (BMGP). Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been directly compensated twenty five thousand dollars from a non-controlling third party for enrollment of BMGP in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.

Reuben Sushman of Beacon Equity Research is a member of the National Association of Securities Dealers, CRD number 1755680.

Beacon Equity Research

Jeff Bishop, (469)-252-3505

press@beaconequity.com

http://www.BeaconEquity.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. JEFF BISHOP http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=70781


'/>"/>
SOURCE BeaconEquity.com
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
7. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
8. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
9. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
10. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
11. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... DUBLIN , Jan 19, 2017 Research and ... has announced the addition ... - Material, Application - Forecast to 2025" report to ... The report provides a detailed analysis on current ... Market forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, LLC, ... and medical device manufacturers and regulators, is proud to announce the worldwide release ... client designed to provide product vigilance departments with the flexibility and ease of ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American ... to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said ... to the existing policy. AMIA recommended that NIH earmark funding for researchers to ...
Breaking Biology Technology:
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
Breaking Biology News(10 mins):